EPL Ltd

AGM notice details

• 43rd EPL AGM on Sept 16, 2026 at 11:00 IST via video conferencing.
• Integrated Annual Report and AGM notice emailed to Members with registered emails.
• Voting cut-off date: Sept 9, 2026; remote e-voting Sept 13-15, 2026.
• Quorum counted for those attending via VC; e-voting closes during AGM.
• NSDL provides e-voting; shareholders advised to register emails via DP or RTA.
• KYC updates required to avoid hold on dividends for physical shareholders.
• Newspaper advertisements published on Aug 22, 2026 to inform AGM.
• No physical meeting venue; attendance via VC only.
• Integrated Annual Report available on EPL site and stock exchange portals.

Unaudited results publication

• Newspaper advertisement for EPL's unaudited standalone and consolidated results for quarter ended 30 June 2026.
• Ads published in Business Standard Mumbai Edition (English) and Navshakti Mumbai Edition (Marathi).
• Board approved the unaudited results at meetings held August 11, 2026.
• Results published in the papers on August 12, 2026; available on EPL website.
• Standalone revenue from operations: 13,879 lakhs; Consolidated revenue: 242,489.85 lakhs.
• Basic EPS: 3.08; Diluted EPS: 3.07 for the quarter.
• Board approval referenced SEBI LODR Regulations; results filed with stock exchanges.
• Full format available on BSE/NSE and EPL's website.
• Audit Committee reviewed results; Board took on record.
• Newspaper ads also on EPL's site.

Meeting Details

• Date: August 11, 2026; conference call for analysts/investors held.
• Event/type: Group conference call; mode not specified.
• Event/organiser: not explicitly mentioned.

Participants

• Key company role involved: Head - Legal, Company Secretary & Compliance Officer (signatory).

Purpose

• Discuss unaudited standalone and consolidated results for quarter ended June 30, 2026.

Additional Notes

• Audio recording of the conference call is available on EPL's website.

Financial highlights

• Q1 FY27 revenue ₹13,879 mn, up 25.3% YoY.
• EBITDA ₹2,612 mn; EBITDA margin 18.8%.
• Underlying EBITDA margin 19.6%.
• PAT declined 1.4% YoY; PBT up 10%.
• Fifteenth consecutive quarter of double-digit EBITDA growth.
• Underlying revenue growth excluding raw-material pass-through: 20%.

Strategic actions and outlook

• Merger with Indovida creates a $1b revenue entity; valuation $2b.
• CCI and eight-country anti-trust approvals secured.
• Guidance raised to high-teens revenue growth for next quarters.
• Underlying EBITDA margin target maintained at 20%.
• EcoVadis Platinum ESG rating; top 1% globally.
• Personal Care & Beyond accounted for 54% of portfolio; growth 25.1% YoY.
• Beauty & Cosmetics and Oral Care growth 23.6% and 23.9% YoY.
• Sustainable tubes contributed 44% of total sales.
• Regional growth: EAP 34.3%, Americas 29.4%, Europe 20.2%, AMESA 17%.
• India revenue growth 19.9%.

Business Overview

• Largest global laminated-tube packaging company for FMCG and Pharma.
• Operates in 11 countries with 21 facilities; 6,000+ employees.
• Focus on sustainable Platina tubes and innovative packaging solutions.

Key Operational Highlights

• Q1FY27 regional revenue growth: AMESA 17%.
• Q1FY27: India revenue up 19.9%.
• Q1FY27: EAP revenue up 34.3%.
• Americas revenue up 29.4%; Europe up 20.2%.
• Underlying EBITDA 19.6%; reported EBITDA 18.8% with pricing pass-through.
• PAT in line; PBT up 10%; ROCE 18.5%.
• Net debt increased due to capex and higher working capital.
• New customer wins in B&C; wallet-share gains in Oral.
• Merger with Indovida announced Mar-2026; CCI approval 26 May 2026.
• 10 jurisdictions filed; 8 approvals secured; NCLT process pending.
• Timeline: merger completion expected in Q4 FY27.

Financial Performance

• Underlying EBITDA margin 19.6%; reported EBITDA 18.8% due to pricing pass-through.
• PAT in line with estimates; YoY PAT down 1.4% due to low base-year ETR.
• PBT up 10%; ROCE 18.5%.
• Net debt increased due to ahead-of-curve capex and higher working capital.

Capital Structure & Liquidity

• Merger would involve new EPL shares issued on completion.
• Timeline: completion in Q4 FY27; NCLT and listing approvals required.

Strategic Priorities & Outlook

• Guidance: high-teens revenue growth expected in near term.
• Strategic focus on scale, profitability, and capital efficiency.
• Capex in new technologies; asset utilization and operating leverage.
• Growth drivers: B&C momentum, Oral care premiumization, regional expansion.
• Sustainability investments to preserve pricing power.

Risks & Mitigation

• Middle East crisis drives input-cost inflation; mitigated by supply security measures.
• Commodity inflation pass-through helps offset cost pressures.

Governance & Leadership

• Merger with Indovida subject to NCLT listing approvals; shareholder meetings on completion.
• CCI approval obtained; anti-trust approvals in 8 jurisdictions.

Standalone highlights

• Revenue from operations Rs 4,003 mn; QoQ rise from Rs 3,531 mn.
• Total income Rs 4,009 mn; QoQ rise from Rs 3,835 mn.
• PBT before exceptional items Rs 296 mn; PAT Rs 220 mn; EPS Rs 0.69.
• Operating margin 18.01%; net margin 5.49%.
• ESOPs granted 7,682; 49,816 shares allotted in quarter.
• Labour Codes impact Rs 59 mn; merger costs Rs 156 mn; year ended 31 Mar 2026.

Consolidated results & segment mix

• Revenue from operations Rs 13,879 mn; total income Rs 13,915 mn for Q1 FY27.
• Net profit after tax Rs 1,006 mn; EPS Rs 3.08.
• Operating margin 19.01% for quarter; year margin 20.26%.
• Geographic mix: AMESA Rs 4,374 mn; EAP Rs 3,602; AMERICAS Rs 3,792; EUROPE Rs 3,214.
• Inter-segment elimination Rs (1,109) mn; total segment result Rs 1,518 mn.

Other notable items

• Labour Codes impact Rs 59 mn; year ended 31 Mar 2026.
• Factory closure cost Rs 67 mn in year ended 31 Mar 2026.
• Merger with Indovida India awaiting approvals; Rs 156 mn incurred.
• ESOP activity: 7,682 options granted; 49,816 shares allotted.

CP issuance details

• Company issued and allotted Commercial Papers aggregating Rs 60 crore.
• ISIN: INE255A14767.
• Issue size Rs 60 crore; 1,200 units.
• Issue date and allotment: July 29, 2026.
• Maturity: October 27, 2026; face value Rs 5,00,000 per unit.
• Discount rate: 7.22% p.a.; yield: 7.35% p.a.
• Listing on NSE is in process; not material to EPL.

CP Issuance Details

• Issued and allotted Commercial Papers aggregating Rs 60 crore on July 27, 2026.
• CP size Rs 60 crore, 1200 units, face value Rs 5,00,000 per unit.
• Issue date and allotment: 27-Jul-2026; maturity: 23-Nov-2026.
• Discount rate 7.37% p.a.; yield rate 7.55% p.a.
• ISIN INE255A14759; listing is planned on NSE.
• Not material in nature to the company.